Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
01 02 2023
Historique:
entrez: 1 2 2023
pubmed: 2 2 2023
medline: 4 2 2023
Statut: epublish

Résumé

To examine the associations between five major adverse pregnancy outcomes and long term risks of ischemic heart disease in mothers. National cohort study. Sweden. All 2 195 266 women with a first singleton delivery in Sweden during 1973-2015. The main outcome measure was incidence of ischemic heart disease from delivery to 2018, identified from nationwide inpatient and outpatient diagnoses. Cox regression was used to calculate hazard ratios for ischemic heart disease associated with preterm delivery, small for gestational age, pre-eclampsia, other hypertensive disorders of pregnancy, and gestational diabetes, adjusting for other adverse pregnancy outcomes and maternal factors. Co-sibling analyses assessed for confounding by shared familial (genetic and environmental) factors. During 53.6 million person years of follow-up, ischemic heart disease was diagnosed in 83 881 (3.8%) women. All five adverse pregnancy outcomes were independently associated with increased risk of ischemic heart disease. In the 10 years after delivery, adjusted hazard ratios for ischemic heart disease associated with specific adverse pregnancy outcomes were 2.09 (95% confidence interval 1.77 to 2.46) for other hypertensive disorders of pregnancy, 1.72 (1.55 to 1.90) for preterm delivery, 1.54 (1.37 to 1.72) for pre-eclampsia, 1.30 (1.09 to 1.56) for gestational diabetes, and 1.10 (1.00 to 1.21) for small for gestational age. The hazard ratios remained significantly increased even 30-46 years after delivery: 1.47 (1.30 to 1.66) for other hypertensive disorders of pregnancy, 1.40 (1.29 to 1.51) for gestational diabetes, 1.32 (1.28 to 1.36) for pre-eclampsia, 1.23 (1.19 to 1.27) for preterm delivery, and 1.16 (1.13 to 1.19) for small for gestational age. These findings were only partially (<45%) explained by shared familial (genetic or environmental) factors. Women who experienced multiple adverse pregnancy outcomes showed further increases in risk (eg, <10 years after delivery, adjusted hazard ratios associated with 1, 2, or ≥3 adverse pregnancy outcomes were 1.29 (1.19 to 1.39), 1.80 (1.59 to 2.03), and 2.26 (1.89 to 2.70), respectively)). In this large national cohort, women who experienced any of five major adverse pregnancy outcomes showed an increased risk for ischemic heart disease up to 46 years after delivery. Women with adverse pregnancy outcomes should be considered for early preventive evaluation and long term risk reduction to help prevent the development of ischemic heart disease.

Identifiants

pubmed: 36724989
doi: 10.1136/bmj-2022-072112
pmc: PMC9890184
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e072112

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the National Heart, Lung, and Blood Institute at the National Institutes of Health, Swedish Research Council, Swedish Heart-Lung Foundation, and ALF project grant, Region Skåne/Lund University, Sweden for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

Circulation. 2021 May 4;143(18):e902-e916
pubmed: 33779213
Trends Cardiovasc Med. 2011 Oct;21(7):188-93
pubmed: 22867697
Circulation. 2020 Aug 18;142(7):711-713
pubmed: 32804569
Cardiol Ther. 2021 Dec;10(2):577-592
pubmed: 34043209
J Am Coll Cardiol. 2019 Dec 3;74(22):2743-2754
pubmed: 31727424
Eur Heart J. 2021 Nov 24;:
pubmed: 34849711
Eur Heart J. 2019 Apr 7;40(14):1113-1120
pubmed: 30596987
J Am Coll Cardiol. 2019 Apr 30;73(16):2106-2116
pubmed: 31023435
J Am Heart Assoc. 2018 Jan 15;7(2):
pubmed: 29335319
Circulation. 2019 Feb 19;139(8):1069-1079
pubmed: 30779636
BMJ. 2020 Aug 19;370:m2533
pubmed: 32816755
Int J Cardiol. 2000 Oct;76(1):17-21
pubmed: 11121592
Circulation. 2016 May 31;133(22):2149-58
pubmed: 27143682
Circulation. 2021 May 25;143(21):2032-2044
pubmed: 33966449
Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2):
pubmed: 28228456
JAMA Pediatr. 2020 Feb 1;174(2):113-114
pubmed: 31816025
Cancer Treat Res. 1995;75:95-112
pubmed: 7640169
Circulation. 2012 Mar 20;125(11):1367-80
pubmed: 22344039
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Epidemiol Rev. 2014;36:57-70
pubmed: 24025350
Hypertens Res. 2018 Apr;41(4):282-289
pubmed: 29449706
Clin Cardiol. 2012 Mar;35(3):160-5
pubmed: 22389120
Eur J Epidemiol. 2018 Oct;33(10):1003-1010
pubmed: 30062549
JAMA Cardiol. 2022 Jan 1;7(1):65-74
pubmed: 34643643
Hypertension. 2011 Oct;58(4):709-15
pubmed: 21844489
J Am Coll Cardiol. 2020 Jul 7;76(1):57-67
pubmed: 32616164
Circulation. 2016 Mar 1;133(9):916-47
pubmed: 26811316
Eur J Epidemiol. 2023 Jan;38(1):109-120
pubmed: 36595114
JAMA Cardiol. 2020 Dec 1;5(12):1390-1398
pubmed: 32936228
Nat Commun. 2020 Nov 25;11(1):5976
pubmed: 33239696
Diabetologia. 2019 Jun;62(6):905-914
pubmed: 30843102
Natl Health Stat Report. 2012 Apr 12;(51):1-28
pubmed: 22803225
Epidemiology. 2011 Sep;22(5):713-7
pubmed: 21558856
Diabetes Res Clin Pract. 2018 Jun;140:324-338
pubmed: 29655653
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Scand J Soc Med. 1990 Jun;18(2):143-8
pubmed: 2367825

Auteurs

Casey Crump (C)

Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA casey.crump@mssm.edu.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Jan Sundquist (J)

Lund University, Centre for Primary Health Care Research, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden.

Mary Ann McLaughlin (MA)

Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Siobhan M Dolan (SM)

Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Usha Govindarajulu (U)

Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Weiva Sieh (W)

Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Kristina Sundquist (K)

Lund University, Centre for Primary Health Care Research, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH